Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XFOR 
X4 Pharmaceuticals Inc (XFOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: XFOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $42.67
1 Year Target Price $42.67
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.07% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.64M USD | Price to earnings Ratio 0.87 | 1Y Target Price 42.67 |
Price to earnings Ratio 0.87 | 1Y Target Price 42.67 | ||
Volume (30-day avg) 5 | Beta 0.66 | 52 Weeks Range 1.81 - 26.97 | Updated Date 07/1/2025 |
52 Weeks Range 1.81 - 26.97 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 46.54% | Operating Margin (TTM) -32.78% |
Management Effectiveness
Return on Assets (TTM) -58.61% | Return on Equity (TTM) 121.75% |
Valuation
Trailing PE 0.87 | Forward PE - | Enterprise Value 4686579 | Price to Sales(TTM) 0.43 |
Enterprise Value 4686579 | Price to Sales(TTM) 0.43 | ||
Enterprise Value to Revenue 0.15 | Enterprise Value to EBITDA 0.19 | Shares Outstanding 7178760 | Shares Floating 4364496 |
Shares Outstanding 7178760 | Shares Floating 4364496 | ||
Percent Insiders 2.43 | Percent Institutions 55.7 |
Analyst Ratings
Rating 3 | Target Price 42.67 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
X4 Pharmaceuticals Inc
Company Overview
History and Background
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and developing novel therapeutics to improve the lives of people with immune system dysfunction. Founded in 2007, X4 is pioneering a new approach to immunology by targeting the CXCR4 pathway.
Core Business Areas
- Rare Diseases: Focuses on the development of therapies for rare genetic diseases characterized by immune deficiencies and chronic inflammation.
- Oncology: Explores the potential of CXCR4 inhibition in cancer treatment, particularly in combination with other therapies.
Leadership and Structure
Paula Ragan is the CEO. The company has a typical biopharmaceutical organizational structure with departments focused on research & development, clinical trials, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Mavorixafor (Xolremdi): A CXCR4 antagonist approved for WHIM syndrome. Market share data is still evolving as it is newly launched, but they are targeting the entire global WHIM syndrome patient population. Competitors are primarily focused on managing the symptoms of WHIM through other therapies, not treating the root cause.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by high risks and long development timelines but also the potential for significant rewards for successful therapies.
Positioning
X4 Pharmaceuticals is a niche player focused on rare diseases within the immunology space. Their competitive advantage lies in their expertise in CXCR4 biology and their first-in-class CXCR4 antagonist.
Total Addressable Market (TAM)
The total addressable market for WHIM syndrome and other potential CXCR4-related indications is estimated to be in the hundreds of millions to billions of dollars. X4 is aiming to capture a significant portion of this market with their targeted therapies.
Upturn SWOT Analysis
Strengths
- First approved CXCR4 antagonist
- Strong intellectual property portfolio
- Experienced management team
- Focus on rare diseases with unmet needs
Weaknesses
- Reliance on a single product (Mavorixafor) for revenue
- High cash burn rate
- Dependence on successful clinical trials for pipeline development
- Potential for competition from other CXCR4 inhibitors or alternative therapies
Opportunities
- Expansion of Mavorixafor to other indications beyond WHIM syndrome
- Development of new CXCR4-targeted therapies
- Partnerships and collaborations with other pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Failure of clinical trials
- Regulatory setbacks
- Competition from other therapies
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- Not publicly known due to Mavorixafor being the first approved CXCR4 inhibitor, therefore no direct competitors with a same mechanism of action (US stock symbols). Competitors would include companies that treat the symptoms of WHIM and similar diseases with different pathways of action, such as Amgen (AMGN) and Novartis (NVS)
Competitive Landscape
X4 Pharmaceuticals has a first-mover advantage in CXCR4 inhibition. However, they face competition from established pharmaceutical companies and other companies developing therapies for similar indications.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth as Mavorixafor was recently approved.
Future Projections: Future growth is dependent on successful commercialization of Mavorixafor and pipeline development. Analyst estimates vary depending on trial outcomes and market penetration.
Recent Initiatives: Commercial launch of Mavorixafor (Xolremdi), ongoing clinical trials for other indications, exploration of partnerships and collaborations.
Summary
X4 Pharmaceuticals is a biopharmaceutical company pioneering therapies targeting the CXCR4 pathway, holding promise for individuals with immune system dysfunctions. The company's recent approval of Mavorixafor marks a critical milestone. Its heavy reliance on a single product and continuous losses need to be balanced against its significant growth potential from its unique technology. Future success hinges on expanding Mavorixafor's applications and managing financial resources effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- X4 Pharmaceuticals Inc. Investor Relations
- Company SEC Filings
- Analyst Reports
- Various Financial News Platforms
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and can vary based on different sources and methodologies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About X4 Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-11-16 | CEO, President & Director Dr. Paula Ragan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | Website https://www.x4pharma.com |
Full time employees 143 | Website https://www.x4pharma.com | ||
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.